Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)’s share price hit a new 52-week high on Tuesday after Svb Leerink raised their price target on the stock from $50.00 to $67.00. Svb Leerink currently has an outperform rating on the stock. Biohaven Pharmaceutical traded as high as $62.57 and last traded at $63.22, with a volume of 11556 shares. The stock had previously closed at $60.88.

Other equities research analysts have also recently issued research reports about the stock. Canaccord Genuity raised their target price on shares of Biohaven Pharmaceutical from $46.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Morgan Stanley cut shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and set a $49.13 target price on the stock. in a research note on Tuesday, April 9th. They noted that the move was a valuation call. Oppenheimer raised their target price on shares of Biohaven Pharmaceutical from $54.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Barclays restated a “hold” rating and set a $52.00 target price on shares of Biohaven Pharmaceutical in a research note on Tuesday, March 19th. Finally, ValuEngine upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $63.01.

In other news, Director Declan Doogan sold 2,078 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $45.48, for a total transaction of $94,507.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Vlad Coric sold 100,000 shares of Biohaven Pharmaceutical stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 437,856 shares of company stock worth $22,279,475. Company insiders own 34.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Flinton Capital Management LLC bought a new stake in shares of Biohaven Pharmaceutical during the fourth quarter valued at approximately $42,000. Neuburgh Advisers LLC bought a new stake in shares of Biohaven Pharmaceutical during the fourth quarter valued at approximately $52,000. Legal & General Group Plc raised its position in shares of Biohaven Pharmaceutical by 14.1% during the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock valued at $196,000 after buying an additional 652 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Biohaven Pharmaceutical during the third quarter valued at approximately $218,000. Finally, Blueshift Asset Management LLC bought a new stake in shares of Biohaven Pharmaceutical during the fourth quarter valued at approximately $306,000. Hedge funds and other institutional investors own 88.91% of the company’s stock.

The stock has a market cap of $2.66 billion, a PE ratio of -10.41 and a beta of 0.50.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Thursday, February 28th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.06). On average, sell-side analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -6.21 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.mareainformativa.com/news/2019/04/24/biohaven-pharmaceutical-bhvn-sets-new-52-week-high-on-analyst-upgrade.html.

Biohaven Pharmaceutical Company Profile (NYSE:BHVN)

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: How to interpret the current ratio

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.